Rocket Pharmaceuticals, Inc. RCKT
NASDAQ · United States · Health Technology
$2.56-0.03 (-1.16%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) said September 15 that the FDA agreed to count three patients treated under the modified RP-A501 protocol toward the pivotal Phase 2 efficacy cohort of 12 male patients. Nine additional patients remain to be enrolled and treated, with dosing expected to finish by mid-2027. Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) is developing RP-A501 […]
Ultragenyx’s second gene therapy approval since August gives it another sellable voucher. Elsewhere, Roche declared success in a blood cancer trial and a cell therapy maker is cutting costs.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.